{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:30:36Z","timestamp":1791639036222,"version":"4.3.4"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2470,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lowering the dose of desoxycorticosterone pivalate (DOCP) for the treatment of dogs with primary hypoadrenocorticism (PH) decreases costs and could lead to increased owner motivation to treat their affected dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy of a low-dose DOCP treatment protocol in dogs with PH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Prospective study, 17 client-owned dogs with naturally occurring PH (12 newly diagnosed, 5 previously treated with fludrocortisone acetate [FC]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Dogs with newly diagnosed PH were started on 1.5\u2009mg\/kg DOCP SC; dogs previously treated with FC were started on 1.0-1.8\u2009mg\/kg DOCP SC. Reevaluations took place at regular intervals for a minimum of 3\u2009months and included clinical examination and determination of serum sodium and potassium concentrations. The DOCP dosage was adjusted to obtain an injection interval of 28-30\u2009days and to keep serum electrolyte concentrations within the reference interval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median (range) follow-up was 16.2\u2009months (4.5-32.3\u2009months). The starting dosage was sufficient in all but 2 dogs and had to be significantly decreased after 2-3\u2009months to a median dosage (range) of 1.1\u2009mg\/kg (0.7-1.8). Dogs 3\u2009years of age or younger needed significantly higher dosages compared to older dogs. None of them, however, needed the 2.2\u2009mg\/kg DOCP dosage, recommended by the manufacturer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>A starting dosage of 1.5\u2009mg\/kg DOCP is effective in controlling clinical signs and serum electrolyte concentrations in the majority of dogs with PH. An additional dose reduction often is needed to maintain an injection interval of 28-30\u2009days. Young and growing animals seem to need higher dosages.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.15475","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T10:50:32Z","timestamp":1552474232000},"page":"1266-1271","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Evaluation of a low-dose desoxycorticosterone pivalate treatment protocol for long-term management of dogs with primary hypoadrenocorticism"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8256-0137","authenticated-orcid":false,"given":"Nadia S.","family":"Sieber-Ruckstuhl","sequence":"first","affiliation":[{"name":"Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia E.","family":"Reusch","sequence":"additional","affiliation":[{"name":"Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Hofer-Inteeworn","sequence":"additional","affiliation":[{"name":"Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kuemmerle-Fraune","sequence":"additional","affiliation":[{"name":"Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9750-4296","authenticated-orcid":false,"given":"Regina","family":"Hofmann-Lehmann","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Vetsuisse Faculty, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6793-8464","authenticated-orcid":false,"given":"Felicitas S.","family":"Boretti","sequence":"additional","affiliation":[{"name":"Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"key":"2026020922042150100_jvim15475-bib-0001","author":"Freedom of Information Summary Percorten\u00ae-V, FDA","year":"1998"},{"key":"2026020922042150100_jvim15475-bib-0002","year":"2015"},{"key":"2026020922042150100_jvim15475-bib-0003","author":"Freedom of Information Summary Zycortal\u00ae, FDA","year":"2016"},{"key":"2026020922042150100_jvim15475-bib-0004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1939-1676.1997.tb00072.x","article-title":"Treatment and long-term follow-up of 205 dogs with hypoadrenocorticism","volume":"11","author":"Kintzer","year":"1997","journal-title":"J Vet Intern Med"},{"key":"2026020922042150100_jvim15475-bib-0005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/avj.12019","article-title":"Lower initial dose desoxycorticosterone pivalate for treatment of canine primary hypoadrenocorticism","volume":"91","author":"Bates","year":"2013","journal-title":"Aust Vet J"},{"key":"2026020922042150100_jvim15475-bib-0006","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/jvim.14828","article-title":"Desoxycorticosterone pivalate duration of action and individualized dosing intervals in dogs with primary hypoadrenocorticism","volume":"31","author":"Jaffey","year":"2017","journal-title":"J Vet Intern Med"},{"key":"2026020922042150100_jvim15475-bib-0007","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/104063879700900307","article-title":"Validation of nonradioactive chemiluminescent immunoassay methods for the analysis of thyroxine and cortisol in blood samples obtained from dogs, cats, and horses","volume":"9","author":"Singh","year":"1997","journal-title":"J Vet Diagn Invest"},{"key":"2026020922042150100_jvim15475-bib-0008","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1939-1676.2009.0328.x","article-title":"Accuracy of an adrenocorticotropic hormone (ACTH) immunoluminometric assay for differentiating ACTH-dependent from ACTH independent hyperadrenocorticism in dogs","volume":"23","author":"Rodriguez Pineiro","year":"2009","journal-title":"J Vet Intern Med"},{"key":"2026020922042150100_jvim15475-bib-0009","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1939-165X.2003.tb00333.x","article-title":"Validation of a chemiluminescent enzyme immunometric assay for plasma adrenocorticotropic hormone in the dog","volume":"32","author":"Scott-Moncrieff","year":"2003","journal-title":"Vet Clin Pathol"},{"key":"2026020922042150100_jvim15475-bib-0010","first-page":"259","article-title":"Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone","volume":"75","author":"Oelkers","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2026020922042150100_jvim15475-bib-0011","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/jvim.12426","article-title":"Use of plasma renin activity to monitor mineralocorticoid treatment in dogs with primary hypoadrenocorticism: desoxycorticosterone versus fludrocortisone","volume":"28","author":"Baumstark","year":"2014","journal-title":"J Vet Intern Med"},{"key":"2026020922042150100_jvim15475-bib-0012","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2460\/javma.1995.206.03.327","article-title":"Effects of desoxycorticosterone pivalate administration on blood pressure in dogs with primary hypoadrenocorticism","volume":"206","author":"Kaplan","year":"1995","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922042150100_jvim15475-bib-0013","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/ki.1980.32","article-title":"Escape from the sodium-retaining effects of mineralocorticoids","volume":"17","author":"Knox","year":"1980","journal-title":"Kidney Int"},{"key":"2026020922042150100_jvim15475-bib-0014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrneph.2009.228","article-title":"Aldosterone escape vs breakthrough","volume":"6","author":"Schrier","year":"2010","journal-title":"Nat Rev Nephrol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.15475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.15475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.15475","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/33\/3\/1266\/66659858\/jvim15475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/33\/3\/1266\/66659858\/jvim15475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:06:07Z","timestamp":1770692767000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/33\/3\/1266\/8448151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.15475","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,5,1]]},"assertion":[{"value":"2018-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}